Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

被引:155
作者
Kinoshita, Yoshikazu [1 ]
Ishimura, Norihisa [1 ]
Ishihara, Shunji [1 ]
机构
[1] Shimane Univ, Sch Med, Dept Gastroenterol & Hepatol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan
基金
日本学术振兴会;
关键词
Adverse effect; Allergic disease; Gastric acid; Gastroesophageal reflux; Ulcer; SPONTANEOUS BACTERIAL PERITONITIS; COMPETITIVE ACID BLOCKER; GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; COMMUNITY-ACQUIRED PNEUMONIA; BONE-MINERAL DENSITY; CLOSTRIDIUM-DIFFICILE INFECTION; ACUTE INTERSTITIAL NEPHRITIS; DUAL ANTIPLATELET THERAPY; CLINICAL-OUTCOMES;
D O I
10.5056/jnm18001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases including gastroesophagealre flux disease and secondary prevention of aspirin/NSAID-induced ulcers. Although clinically important adverse effects of PPIs can occur, just as with other drugs, those are not frequently observed during or after administration. Thus, PPIs are regarded as relatively safe and considered to be clinically beneficial. Recently, PPIs have become frequently administered to patients with functional gastrointestinal diseases or primary prevention of drug-related gastroduodenal damage, even though their beneficial effects for those conditions have not been fully confirmed. PPIs tend to be given for conditions in which the necessity of the drug has not been clarified, thus otherwise rare adverse effects are presented as clinically relevant. Although several PPI-related adverse effects have been reported, their clinical relevance is not yet clear, since the evidence reported in those studies is not at a high enough level, as the majority are based on retrospective observational studies and the reported hazard ratios are low. It is important to administer PPIs only for patients who will gain a substantial clinical benefit and to continue to investigate their adverse effects with high quality prospective studies.
引用
收藏
页码:182 / 196
页数:15
相关论文
共 155 条
[21]   Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies [J].
Cheungpasitporn, Wisit ;
Thongprayoon, Charat ;
Kittanamongkolchai, Wonngarm ;
Srivali, Narat ;
Edmonds, Peter J. ;
Ungprasert, Patompong ;
O'Corragain, Oisin A. ;
Korpaisarn, Sira ;
Erickson, Stephen B. .
RENAL FAILURE, 2015, 37 (07) :1237-1241
[22]  
Chiba T, 2000, J GASTROENTEROL, V35, pU11
[23]   Lessons from two cases of anaphylaxis to proton pump inhibitors [J].
Choi, S. -W. ;
Han, J. -M. ;
Bae, Y. -J. ;
Lee, Y. S. ;
Cho, Y. S. ;
Moon, H. -B. ;
Kim, T. -B. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (05) :614-616
[24]   Proton pump inhibitor-associated gastric polyps - A retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics [J].
Choudhry, U ;
Boyce, HW ;
Coppola, D .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 110 (05) :615-621
[25]   Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production [J].
Colucci, R ;
Blandizzi, C ;
Tanini, M ;
Vassalle, C ;
Breschi, MC ;
Del Tacca, M .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (03) :338-348
[26]   Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients [J].
Corley, Douglas A. ;
Kubo, Ai ;
Zhao, Wei ;
Quesenberry, Charles .
GASTROENTEROLOGY, 2010, 139 (01) :93-101
[27]   Proton Pump Inhibitors as a Risk Factor for Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Patients With Cirrhosis With Ascites [J].
Dam, Gitte ;
Vilstrup, Hendrik ;
Watson, Hugh ;
Jepsen, Peter .
HEPATOLOGY, 2016, 64 (04) :1265-1272
[28]   Omeprazole in oesophageal reflux disease [J].
Dawson, R ;
Manson, JM .
LANCET, 2000, 356 (9243) :1770-1771
[29]  
Delle Fave Gianfranco, 2004, Neuroendocrinology, V80 Suppl 1, P16
[30]   A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease [J].
Dent, John ;
Kahrilas, Peter J. ;
Hatlebakk, Jan ;
Vakil, Nimish ;
Denison, Hans ;
Franzen, Stefan ;
Lundborg, Per .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (01) :20-26